Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
AssigneeTriplet Therapeutics, Inc.
InventorsNessan Anthony Bermingham, Brian R. Bettencourt, Pei Ge
Life of this patent
Estimating the term…
Abstract
The present disclosure features useful compositions and methods to treat nucleotide repeat expansion disorders, e.g., in a subject in need thereof. In some aspects, the compositions and methods described herein are useful in the treatment of disorders associated with MSH3 activity.
Claims36
-12. (canceled)
A single-stranded oligonucleotide of 15-30 linked nucleotides in length, wherein the oligonucleotide, or a portion thereof, is at least 95% complementary to at least 15 contiguous nucleobases at positions 2685-2714 of SEQ ID NO:
- 614, or a pharmaceutically acceptable salt thereof.
-16. (canceled)
-26. (canceled)
-31. (canceled)
-112. (canceled)
-132. (canceled)
-159. (canceled)
-162. (canceled)
-167. (canceled)
(canceled)
-180. (canceled)
-183. (canceled)
-205. (canceled)
Dependencies are inferred from the claim text.